Group 1: Company Overview - Chutian Technology Co., Ltd. is a well-known supplier of intelligent pharmaceutical equipment and overall technical solutions, focusing on various fields including chemical drugs, raw materials, biological drugs, and traditional Chinese medicine [2] - The company has expanded into the medical beauty and cosmetics sectors as part of its development strategy [2] Group 2: Financial Performance - The company aims to achieve profitability in 2025 after a loss in the first quarter, with expectations to turn around by mid-year or the third quarter through improved operational efficiency [2] - In 2024, Romaco Group reported a revenue of €208.75 million, a 1.26% increase year-on-year, but a net profit decline of 91.08% [4] Group 3: Order and Revenue Recognition - Domestic main engine orders are recognized upon obtaining customer-signed installation acceptance certificates, while international orders are recognized upon obtaining customs declarations and bills of lading [3] - The manufacturing cycle for main products typically ranges from 3 to 9 months, with delivery influenced by customer site conditions and project progress [2] Group 4: Impact of Tariffs - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. account for a very small portion of overall revenue [3] - The company has reduced reliance on direct imports from the U.S. by developing core components in-house and utilizing domestic or alternative imported brands [3] Group 5: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international competitiveness [5] - In 2024, domestic exports exceeded 1.2 billion, with products entering high-end markets in Europe [6] Group 6: New Products and Business Development - The company has made significant progress in the fields of peptides, medical beauty, and blood products, establishing a smart factory for beauty products [6] - Chutian Technology has set up a joint venture in peptide synthesis, with total assets of approximately ¥15.61 million and a net loss of ¥2.22 million in 2024 [6]